Lu-177 production begins at Canada’s Bruce NPP

November 1, 2022, 1:27PMNuclear News
Bruce's Unit 7 is now producing Lutetium-177, used in targeted cancer therapeutics. (Photo: Bruce Power)

An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM) announced they have begun commercial production of lutetium-177 using Unit 7 of the Bruce nuclear power plant in Kincardine, Ontario. According to the companies, this marks the first time a commercial power reactor has been used to commercially produce short-lived medical radioisotopes.

To continue reading, log in or create a free account!

Related Articles